---
title: "Roivant Sciences Ltd. FY 2026: Revenue $8.26M, EPS ($0.54) — 10-K Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287056209.md"
description: "Roivant Sciences Ltd. reported FY 2026 results with revenue of $8.26M, a 71.6% decline from $29.05M, and a net loss of $299.77M, widening from $171.98M. Diluted EPS fell to ($0.54). The revenue drop was attributed to lower license income and increased R&D spending, which rose to $681.8M. The company recognized a $770.2M litigation settlement gain and focused on core clinical priorities following strategic divestitures."
datetime: "2026-05-20T11:25:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287056209.md)
  - [en](https://longbridge.com/en/news/287056209.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287056209.md)
---

# Roivant Sciences Ltd. FY 2026: Revenue $8.26M, EPS ($0.54) — 10-K Summary

Roivant Sciences Ltd. reported fiscal 2026 results in its 10-K, with revenue falling to $8.26M and a net loss widening to ($299.77M), or diluted EPS of ($0.54), driven by lower license income following divestitures and higher R&D investment.

**Financial Highlights**

Metric

Current year

Prior year

YoY change

Revenue¹

$8.26M

$29.05M

(71.6%)

Net income²

($299.77M)

($171.98M)

(74.3%)

Diluted EPS³

($0.54)

($0.24)

(125%)

_¹ Reported as “Revenue”. ² Reported as “Net (loss) income attributable to Roivant Sciences Ltd.”. ³ Reported as “income per common share, diluted”._

**Business Highlights**

-   Revenue and operations mix shifted after the sale of Genevant-related license streams and completed divestitures of Telavant and Dermavant, driving the revenue decline to $8.3M in 2026.
-   R&D spending increased to support late‑stage programs including brepocitinib, IMVT‑1402 and mosliciguat; total R&D rose to $681.8M for the year.
-   Company recognized a $770.2M litigation settlement gain and reported progress on pivotal trials and regulatory milestones that support near‑term funding stability.
-   Strategic divestitures monetized noncore assets and refocused capital and resources toward core "Vants" and clinical priorities.

Original SEC Filing: Roivant Sciences Ltd. \[ ROIV \] - 10-K - May. 20, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ROIV.US](https://longbridge.com/en/quote/ROIV.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

- [Roivant Sciences Ltd. Stock 12‑Month Price Target Raised to $36.68, Implies 30% Upside](https://longbridge.com/en/news/287126493.md)
- [Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share](https://longbridge.com/en/news/286966420.md)
- [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md)
- [Shah Capital Management Will Vote ‘No' Across Five Proposals On Novavax's June 18 Ballot - SEC Filing](https://longbridge.com/en/news/286565204.md)
- [Lantern Pharma raises capital, plans AI platform spinoff](https://longbridge.com/en/news/286480334.md)